ClinicalTrials.gov
ClinicalTrials.gov Menu

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00853372
Recruitment Status : Active, not recruiting
First Posted : March 2, 2009
Last Update Posted : March 29, 2018
Sponsor:
Information provided by (Responsible Party):
Amgen

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : August 8, 2011
  Estimated Study Completion Date : November 30, 2018
  Certification/Extension First Submitted : November 2, 2015